Abstract
Thymoquinone (TQ), the bioactive constituent of Nigella Sativa seeds, is a well-known natural compound for the management of several types of cancers. The anti-cancer properties of thymoquinone are thought to be operated via intervening with various oncogenic pathways, prevention of inflammation and oxidative stress, inhibition of angiogenesis and metastasis, and induction of apoptosis, as well as up-regulation and down-regulation of specific tumor suppressor genes and tumor promoting genes, respectively. The proliferation of various tumor cells is inhibited by TQ via induction of cell cycle arrest, disruption of the microtubule organization, and downregulating cell survival protein expression. TQ induces G1 phase cell cycle arrest in human breast cancer, colon cancer and osteosarcoma cells through inhibiting the activation of cyclin E or cyclin D and up-regulating p27 and p21, a cyclin dependent kinase (Cdk) inhibitor. TQ concentration is a significant factor in targeting a particular cell cycle phase. While high concentration of TQ induces G2 phase arrest in human breast cancer (MCF-7) cells, low concentration causes S phase arrest. This review article provides mechanistic insights into the anticancer properties of thymoquinone.
Keywords: Thymoquinone, nigella sativa, angiogenesis, metastasis, invasion, cell cycle, inflammation, oxidative stress.
Combinatorial Chemistry & High Throughput Screening
Title:Molecular Mechanisms of Thymoquinone as Anticancer Agent
Volume: 24 Issue: 10
Author(s): Fatma Alhmied, Ali Alammar, Bayan Alsultan, Muruj Alshehri and Faheem Hyder Pottoo*
Affiliation:
- Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O BOX 1982, Dammam 31441,Saudi Arabia
Keywords: Thymoquinone, nigella sativa, angiogenesis, metastasis, invasion, cell cycle, inflammation, oxidative stress.
Abstract: Thymoquinone (TQ), the bioactive constituent of Nigella Sativa seeds, is a well-known natural compound for the management of several types of cancers. The anti-cancer properties of thymoquinone are thought to be operated via intervening with various oncogenic pathways, prevention of inflammation and oxidative stress, inhibition of angiogenesis and metastasis, and induction of apoptosis, as well as up-regulation and down-regulation of specific tumor suppressor genes and tumor promoting genes, respectively. The proliferation of various tumor cells is inhibited by TQ via induction of cell cycle arrest, disruption of the microtubule organization, and downregulating cell survival protein expression. TQ induces G1 phase cell cycle arrest in human breast cancer, colon cancer and osteosarcoma cells through inhibiting the activation of cyclin E or cyclin D and up-regulating p27 and p21, a cyclin dependent kinase (Cdk) inhibitor. TQ concentration is a significant factor in targeting a particular cell cycle phase. While high concentration of TQ induces G2 phase arrest in human breast cancer (MCF-7) cells, low concentration causes S phase arrest. This review article provides mechanistic insights into the anticancer properties of thymoquinone.
Export Options
About this article
Cite this article as:
Alhmied Fatma , Alammar Ali , Alsultan Bayan , Alshehri Muruj and Pottoo Hyder Faheem *, Molecular Mechanisms of Thymoquinone as Anticancer Agent, Combinatorial Chemistry & High Throughput Screening 2021; 24 (10) . https://dx.doi.org/10.2174/1386207323999201027225305
DOI https://dx.doi.org/10.2174/1386207323999201027225305 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry The DREAM of Pain Relief
Current Rheumatology Reviews Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Cellular Sensitivity to β-Diketonato Complexes of Ruthenium(III), Chromium(III) and Rhodium(III)
Medicinal Chemistry MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
Current Cancer Drug Targets New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry